Get the Stockscreener App
1.1743
11.84%
0.1243
Pre-market:
1.23
0.0557
+4.74%
Biomea Fusion Inc stock is traded at $1.1743, with a volume of 1.54M.
It is up +11.84% in the last 24 hours and down -6.80% over the past month.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
See More
Previous Close:
$1.05
Open:
$1.04
24h Volume:
1.54M
Relative Volume:
0.85
Market Cap:
$83.03M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-0.2928
EPS:
-4.01
Net Cash Flow:
$-113.02M
1W Performance:
+9.75%
1M Performance:
-6.80%
6M Performance:
-58.94%
1Y Performance:
-82.47%
1-Day Range:
$1.0202
$1.18
1-Week Range:
$0.95
$1.18
52-Week Range:
$0.8719
$6.79
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.1743 | 74.24M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-25 | Initiated | Jefferies | Buy |
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
BMEA Insider Trading - Quiver Quantitative
Biomea Fusion Interim CEO Increases Stake with 100,000 Shares Purchase - TradingView
Is Biomea Fusion Inc. stock a buy before product launches2025 Valuation Update & Fast Exit/Entry Strategy Plans - Newser
Biomea Fusion (BMEA) Stock Analysis Report | Financials & Insights - Benzinga
Biomea Fusion Director Rainer M Erdtmann Acquires 50,000 Shares - TradingView
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion to present long-term diabetes drug data at WCIRDC - Investing.com Canada
Biomea Fusion announces breakthrough data presentation at WCIRDC - Traders Union
Biomea Fusion to Present Long-Term Icovamenib Data at 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease - Quiver Quantitative
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion (Nasdaq: BMEA) to present icovamenib β-cell data in insulin-deficient T2D - Stock Titan
Biomea Fusion (Nasdaq: BMEA) Grants 7,500-Share Inducement Option to New Employee - Stock Titan
Aisling Capital Management LP Purchases 1,250,000 Shares of Biomea Fusion, Inc. $BMEA - MarketBeat
Published on: 2025-11-30 10:58:22 - BỘ NỘI VỤ
Biomea Fusion Inc Stock Analysis and ForecastMoving Average Crossovers & Capital Allocation Recommendations - earlytimes.in
Why analysts remain bullish on Biomea Fusion Inc. stock2025 Market Trends & Real-Time Buy Signal Notifications - moha.gov.vn
Form 8-KCurrent report - ADVFN
Can Biomea Fusion Inc. stock outperform in 2025 bull marketTrade Entry Summary & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Will Biomea Fusion Inc. stock return to pre crisis levelsJuly 2025 Catalysts & Long-Term Safe Return Strategies - BỘ NỘI VỤ
Biomea Fusion set to engage at major investor conferences - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
Biomea Fusion to Participate at Upcoming Investor Conferences - Investing News Network
Is the Smart Money Moving Into 52 Weeks Entertainment Limited Institutional Buying TrendsTechnical Analysis Insights & Fast Growing Investment Ideas - earlytimes.in
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Is Biomea Fusion Inc. a candidate for recovery playBreakout Watch & Capital Efficient Trade Techniques - newser.com
Is Biomea Fusion Inc. stock a dividend growth opportunity2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Why Biomea Fusion Inc. stock could be next big winnerEarnings Overview Report & Low Risk High Win Rate Picks - newser.com
Top chart patterns to watch in Biomea Fusion Inc.Earnings Miss & Real-Time Chart Breakout Alerts - newser.com
Biomea Fusion : Corporate Presentation Slidedeck 4Q 2025 - marketscreener.com
JPMorgan downgrades Biomea Fusion stock to Underweight on T2D data concerns - Investing.com Australia
Can Biomea Fusion Inc. stock rebound after recent weakness2025 Market Outlook & Proven Capital Preservation Tips - newser.com
Is Biomea Fusion Inc. stock trading at a premium valuation2025 Fundamental Recap & Smart Allocation Stock Tips - newser.com
How risky is Biomea Fusion Inc. stock nowDollar Strength & Low Drawdown Momentum Trade Ideas - newser.com
Is Biomea Fusion Inc. stock dividend yield sustainable2025 Short Interest & Daily Risk Controlled Trade Plans - newser.com
Is Biomea Fusion Inc. trending in predictive chart modelsJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Biomea stock sinks 16% after Phase 2 data release - MSN
Can trapped investors hope for a rebound in Biomea Fusion Inc.2025 Market Overview & Verified High Yield Trade Plans - newser.com
Long term hold vs stop loss in Biomea Fusion Inc.Weekly Market Outlook & Daily Profit Focused Screening - newser.com
Real time pattern detection on Biomea Fusion Inc. stockEarnings Miss & Expert Verified Movement Alerts - newser.com
Biomea Fusion explores breakthrough in menin inhibition for diabetes - Traders Union
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):